D-amphetamine and antipsychotic drug effects on latent

inhibition in mice lacking dopamine D2 receptors by Bay-Richter, C. et al.
OPEN
D-Amphetamine and Antipsychotic Drug Effects on Latent
Inhibition in Mice Lacking Dopamine D2 Receptors
C Bay-Richter1,5, MJ O’Callaghan 1,5, N Mathur1, CMP O’Tuathaigh2, DM Heery3, KCF Fone4,
JL Waddington2 and PM Moran*,1
1School of Psychology, University of Nottingham, Nottingham, UK; 2Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland,
St Stephens Green, Dublin, Ireland; 3School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, UK; 4School of
Biomedical Sciences, University of Nottingham, Nottingham, UK
Drugs that induce psychosis, such as D-amphetamine (AMP), and those that alleviate it, such as antipsychotics, are suggested to exert
behavioral effects via dopamine receptor D2 (D2). All antipsychotic drugs are D2 antagonists, but D2 antagonism underlies the severe and
debilitating side effects of these drugs; it is therefore important to know whether D2 is necessary for their behavioral effects. Using
D2-null mice (Drd2 / ), we first investigated whether D2 is required for AMP disruption of latent inhibition (LI). LI is a process of
learning to ignore irrelevant stimuli. Disruption of LI by AMP models impaired attention and abnormal salience allocation consequent to
dysregulated dopamine relevant to schizophrenia. AMP disruption of LI was seen in both wild-type (WT) and Drd2 / . This was in
contrast to AMP-induced locomotor hyperactivity, which was reduced in Drd2 / . AMP disruption of LI was attenuated in mice lacking
dopamine receptor D1 (Drd1 / ), suggesting that D1 may play a role in AMP disruption of LI. Further supporting this possibility, we
found that D1 antagonist SKF83566 attenuated AMP disruption of LI in WT. Remarkably, both haloperidol and clozapine attenuated
AMP disruption of LI in Drd2 / . This demonstrates that antipsychotic drugs can attenuate AMP disruption of learning to ignore
irrelevant stimuli in the absence of D2 receptors. Data suggest that D2 is not essential either for AMP to disrupt or for antipsychotic drugs
to reverse AMP disruption of learning to ignore irrelevant stimuli and further that D1 merits investigation in the mediation of AMP
disruption of these processes.
Neuropsychopharmacology (2013) 38, 1512–1520; doi:10.1038/npp.2013.50; published online 27 March 2013
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INTRODUCTION
Dopamine (DA) receptor D2 (D2) blockade is common to all
antipsychotic drugs and correlates most closely with clinical
efficacy (Howes et al, 2009; Meltzer et al, 1989; Seeman et al,
1976). Antipsychotics, however, have affinities for multiple
neurotransmitter and peptide receptors, and it is still
unknown whether D2 is essential for their behavioral effects.
There is a therapeutic imperative to establish whether
activity at D2 is obligatory for antipsychotic drug action, as
D2 blockade is also associated with extrapyramidal motor
symptoms and tardive dyskinesia, which limit compliance
(Fleischhacker et al, 1994; Kapur et al, 2000). There is
pharmacological evidence to challenge the view that
action at D2 may be solely responsible for antipsychotic
drug effects. Newer or ‘atypical’ antipsychotics such as
clozapine, while having equivalent clinical efficacy to older
‘typical’ drugs such as haloperidol, have affinity for multiple
monoamine and peptide receptors (Meltzer et al, 1989). The
therapeutic efficacy of ‘atypical’ antipsychotics can occur at
doses that produce much lower occupancy of D2 than typical
antipsychotics, although this may be explained in terms of
faster rate of dissociation from the receptor (Kapur and
Seeman, 2001). For the atypical antipsychotics clozapine and
quetiapine, no correlation is found between D2 occupancy and
reduction in clinical scores (Yilmaz et al, 2012). There is also
dissociation between the motor side effects and clinical efficacy
of antipsychotic drugs, despite both being presumed to be
mediated by D2 (Natesan et al, 2006). New putative therapies
such as metabotropic glutamate receptor agonists intended to
circumvent D2 interaction may indirectly interact with D2 (Patil
et al, 2007; Seeman and Guan, 2009). The broad pharmaco-
logical profile of antipsychotics makes it difficult to study the
functional role of individual receptors in specific behavioral
effects using drugs and no specific D2 antagonists exist. Here,
we used a null mouse approach to investigate whether D2 is
necessary for antipsychotic drugs to modify salience allocation
processes disrupted by D-amphetamine (AMP), tested using
the learning phenomenon of latent inhibition (LI).
Symptoms of schizophrenia such as hallucinations and
delusions have been suggested to reflect disruption in
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processes that allocate attention or salience to features of
the environment. This is considered to be consequent to
dysregulated DA transmission and to be remediated by
antipsychotic drugs, presumed to be via D2 blockade,
although this remains unknown (Gray et al, 1991; Kapur
et al, 2005; Howes et al, 2009). LI is widely used in animal
models of schizophrenia as an index of the mechanism
through which salience or associability (attention to and
readiness to form associations) is conferred on stimuli on
the basis of how much experience the animal has had of
them (Lubow, 2005; Weiner and Arad, 2009). LI is
demonstrated experimentally as reduced learning of a
conditioned stimulus (CS)–unconditioned stimulus (US)
association in a group pre-exposed to that stimulus without
reinforcement (pre-exposed, PE) compared with a group
without such pre-exposure (non-pre-exposed, NPE). Many,
although not all, studies show that patients with schizo-
phrenia display abnormalities in LI, which may depend on
the stage of illness (Weiner and Arad, 2009). In rats and
humans, antipsychotic drugs such as haloperidol and
clozapine potentiate low LI (Moser et al, 2000; Weiner,
2003; Weiner and Arad, 2009). On the other hand,
psychotomimetic drugs that induce psychosis, such as
AMP that inter alia increase DA release, disrupt LI.
Antipsychotic drugs attenuate this disruption in humans,
rats, and mice (Chang et al, 2007; Gray et al, 1992; Moser
et al, 2000; Weiner, 2003).
Experiments using D2-null mice (Drd2 / ) mice
suggest that D2 is essential for the behavioral and neural
effects of AMP, such as methamphetamine hyperactivity,
disruption of prepulse inhibition of the acoustic startle
response, and DA release (Boulay et al, 1999; Kelly et al,
1998; Schmitz et al, 2001). It is unknown whether D2 is
essential for disruption of LI by AMP. Direct stimulation
of D2 by the agonist apomorphine has been shown not
to disrupt LI (Lacroix et al, 2000), suggesting that D2
activation does not play a role in LI disruption, but later
reports have shown that apomorphine can disrupt LI (Melo
et al, 2009; Shao et al, 2010). This study aimed first to
investigate whether D2 is essential for AMP-induced
disruption of LI. The second aim was to investigate whether
D2 is required for antipsychotic drugs to attenuate AMPH
disruption of LI, which we found to be intact in Drd2 /
mice. The third aim was to further determine the
mechanism by which AMP disrupts LI and to investigate
whether D1 is important for AMP disruption of LI.
MATERIALS AND METHODS
Animals
The original F2 hybrid strains were generated as reported
previously (Drago et al, 1994; Kelly et al, 1997). Congenic D1
and D2 lines were established by repeatedly backcrossing
heterozygous mutants to wild-type (WT) C57BL/6 for
at least 14 generations; homozygous DA receptor D1
(Drd1 / ) and Drd2 / mice and WT (Drd1þ /þ
and Drd2þ /þ mice) littermates were then bred by
heterozygous intermatings of congenic heterozygote mu-
tants (Waddington et al, 2005). Male and female ( / and
þ /þ ) littermates were used at 10–20 weeks of age. In
experiments involving SKF83566, C57BL/6 mice were used,
which were purchased from Charles River UK (Kent, UK)
and Charles River (Wilmington, MA). Mice were housed
1–4 per cage under a 12 h light : 12 h dark cycle (lights on at
0700 hours) and constant temperature (20±2 1C) and
humidity (40–60%), with food available ad libitum. Mice
were subjected to daily water restriction periods of 23 h
throughout LI experiments, with 1 h free access to water
in their home cages after each experimental session. All
experiments were carried out in accordance with local and
national regulations on animal experimentation, and project
license authority under the Animals (Scientific Procedures)
Act, UK 1986; UK home Office Project licenses No: 40/2883
and its renewal as 40/3501.
Genotyping
This was performed by PCR using genomic DNA extracted
from ear biopsies, as described previously (Bay-Richter
et al, 2009).
Latent Inhibition
Experiments were carried out in six identical conditioning
chambers and the LI protocol was the same as that
described previously in detail (Bay-Richter et al, 2009).
For further details of the apparatus used, see Supplementary
Information. Briefly it consisted of the following:
Water restriction (Days 1–7): Mice were placed on 23-h
water restriction 7 days before and throughout the
experiment.
Pretraining (Days 8–13): Mice were placed in chambers
for 15min and the number of licks was recorded.
Pre-exposure (Day 14): Mice were placed in chambers
with no water present. They were given 60 presentations of
a 5-s 85-dB tone with an interstimulus interval of 15 s
(PE group); NPE control mice were placed in the chambers
for the same amount of time but received no tone
pre-exposures.
Conditioning (Day 15): Mice were placed in chambers
with no water present. After 2min, two tone–footshock
pairings were presented. Each tone was of 5-s duration and
followed by a 1-s 0.38-mA footshock and an intertrial
interval of 2.5min; mice remained in the chamber for
2.5min following the second shock presentation.
Re-baseline lick training (Days 16 and 17): Mice were
placed in chambers for 15min and given free access to the
water sipper to re-establish licking. Mice that did not
complete 4300 licks continuously were excluded from the
experiment and did not continue to the test day (two mice
in experiment 1 and two in experiment 2).
Test (Day 18): Mice were placed in chambers with free
access to the water sipper. The number of licks was
recorded and time taken to complete licks 80–90 (A) and
90–100 (B) recorded. After completion of 90 licks, the tone
was presented until the mouse reached lick 100 or 600 s had
elapsed. A suppression ratio (SR) was calculated according
to the formula A/(AþB) yielding a scale of 0 to 0.5.
As logarithmic transformation did not normalize data in
all experiments, SR was therefore considered the most
appropriate measure.
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Spontaneous Locomotor Activity
This was recorded for 30min using videotracking of an
open field as described previously (Bay-Richter et al, 2009).
For further details of the apparatus used and the procedure,
see Supplementary Information.
Experimental Design and Statistics
Statistics were performed using SPSS (Versions 16 (2007)
and 18 (2009); SPSS Chicago, IL). For LI experiments,
analysis of variance (ANOVA) was used. Post hoc tests
comprised planned T-tests with Bonferroni correction for a
slippage for genotype, drug treatment group, and NPE vs PE
comparisons as appropriate. Data were collapsed across sex
as there was no significant effect of sex and no interactions
with treatment, exposure, or genotype in any experiment.
Experiments in Drd1 /mice were explicitly conducted in
females because of baseline sex differences in LI previously
identified by us; male and female Drd2 /mice and
female Drd1 /mice show comparable LI, but male
Drd1 /mice do not show LI; hence, AMP disruption
could not be evaluated in the present conditions in males
(Bay-Richter et al, 2009). Locomotor activity experiments
used split-plot ANOVA with genotype and drug treatment
group as between-group factors and 5-min time bin as
repeated-measures factor. Post hoc comparisons were
performed as described for LI experiments. The n numbers
per experiment were: 30 (9F, 21M) Drd2þ /þ and 19 (9F,
10M) Drd2 / (Figure 1a); 18 (7F, 11M) Drd2þ /þ and
12 (6M, 6F) Drd2 / (Figure 1b); 16 Drd2þ /þ (55F,
61M) and 127 (62F, 65M) Drd2 / (Figure 2); 72F
Drd1þ /þ and 57F Drd1 / (Figure 3a); 46 (23F, 23M)
Drd1þ /þ and 34 (17F, 17M) Drd1 / (Figure 3b); and
138 C57BL/6 (70F, 68M) (Figure 4). In all LI experiments,
groups did not differ in their times to complete licks 80–90
(time A) nor were there any effects of sex or interaction
between sex and other variables (all F valueso1). Owing to
the large number of experimental groups required to allow
simultaneous evaluation of clozapine and haloperidol, and
requirement for age, sex, and littermate matching, the
experiment in Figure 2 was carried out in four matched
cohort replications; there were neither significant effects of
cohort on SR nor significant interactions with exposure,
drug treatment, or genotype (all F values o1.5).
Drugs and Administration
AMP sulfate (Sigma-Aldrich, Dorset, UK) was dissolved in
sterile 0.9% (w/v) saline and a dose of 2.5mg/kg was used in
all experiments. SKF83566 (Tocris, Bristol, UK) was
dissolved in 0.9% NaCl mixed with a few drops of tartaric
acid and buffered to pH 6.5 with NaOH. Doses of 0.01 and
0.1mg/kg were used. Haloperidol and clozapine (Sigma-
Aldrich) were dissolved in 25 ml glacial acetic acid and
buffered to pH 6.5 using 0.1mM NaOH before final dilution
in sterile 0.9% saline to appropriate concentrations (0.1mg/
kg for haloperidol; 2.5mg/kg for clozapine); controls
received vehicle to the same injection volumes (10ml/kg).
Doses of AMP (2.5mg/kg, intraperitoneally) and haloper-
idol (0.1mg/kg, intraperitoneally) were based on previously
established dosage for LI in mice (Chang et al, 2007; Meyer
et al, 2004). The dose of clozapine used was lower than
published reports (Lipina et al, 2005), as significant
sedation occurred in our hands at published effective doses.
For mice receiving AMP in combination with either
haloperidol, clozapine, or SKF83566, the drug was adminis-
tered 5min before AMP, with control mice receiving a
matched number of vehicle injections. All injections were
given intraperitoneal 30min before both pre-exposure and
conditioning sessions (LI) or both habituation and testing
(locomotion). The two injection regimen is based on a
number of studies, which show that two injections of
AMPH, one before pre-exposure and one before condition-
ing, are required to disrupt LI (Weiner et al, 1988; although
see Young et al, 2005). The same regimen was then
maintained to enable direct comparison at the same doses
in locomotor activity experiments.
Figure 1 D-Amphetamine (AMP) disruption of latent inhibition (LI) is
similar in wild-type (WT) and Drd2 / (a). Vehicle-treated WT
(WT-Veh) and vehicle-treated Drd2 / (Drd2 / -Veh) mice show LI
(higher suppression ratio (SR) in pre-exposed (PE) vs non-pre-exposed
(NPE)), while D-amphetamine-treated WT (WT-AMP) and D-ampheta-
mine-treated Drd2 / (Drd2 / -AMP) mice do not. AMP locomotor
hyperactivity seen in WT is blunted in Drd2 / mice (b). *Po0.05 NPE
vs PE, same genotype and drug; þPo0.05 vs vehicle same genotype for
PE; and yPo0.05, yyPo0.001 vs vehicle same genotype and time bin.
Drd2 / , D2-null mice.
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First experiments investigated effects of AMP on LI and
locomotor activity in Drd2þ /þ and Drd2 / . Subse-
quently, effects of the typical D2 antipsychotic haloperidol
and the atypical antipsychotic clozapine on AMP disruption
of LI were investigated. To evaluate a potential role for D1 in
AMP disruption of LI, a series of experiments investigated
AMP effects on LI and locomotor activity in Drd1þ /þ and
Drd1 / and of the D1 antagonist SKF83566 on AMP
disruption of LI.
RESULTS
AMP Reduction of LI in Drd2 / Mice
AMP disrupted LI in Drd2 / mice (Figure 1a). There was
an effect of pre-exposure (F(1,41)¼ 10.89, Po0.01), treat-
ment (F(1,41)¼ 10.78, Po0.01), and a pre-exposure
treatment interaction (F(1,41)¼ 10.20, Po0.01). There was
a significant difference between AMP and vehicle in the PE
condition (T8¼ 2.749, Po0.05) and NPE vs PE (T8¼ 2.741,
Po0.05) in Drd2 / mice. There was no significant effect
of genotype nor interaction between genotype and other
factors. In Drd2þ /þ mice, there was no significant
difference between AMP and vehicle in the PE condition;
however, NPE was significantly different from PE condition,
indicating LI in the vehicle (T24¼  2.7, Po0.05) but not
the AMP group (T21¼ 0.4).
AMP Locomotor Hyperactivity in Drd2 / Mice
AMP locomotor hyperactivity was seen in WT mice, but was
blunted in Drd2 / mice using the same dose and
regimen of AMP as described for LI experiments
(Figure 1b). There was a significant effect of genotype
(F(1,22)¼ 47.23, Po0.001), drug treatment (F(1,22)¼ 33.96,
Po0.001), and a genotype drug treatment interaction
(F(1,22)¼ 8.42, Po0.01). There was a significant effect of
time bin (F(5,110)¼ 13.07, Po0.001) and an interaction
Figure 2 Haloperidol (Hal) and clozapine (Cloz) attenuate disruption of
latent inhibition (LI) by D-amphetamine (AMP) in both wild-type (WT; a)
and D2 / mice (Drd2 / ; b); *Po0.05, **Po0.01, non-pre-exposed
(NPE) vs pre-exposed (PE) same genotype and drug; þPo0.05, þ þ
Po0.01 vs AMP-PE same genotype. Drd2 / , D2-null mice.
Figure 3 D-Amphetamine (AMP) disruption of latent inhibition (LI)
(60 pre-exposed (PE)) is attenuated in Drd1 / mice (a), but locomotor
hyperactivity is not (b). *Po0.05 non-pre-exposed (NPE) vs PE same
genotype and drug; þPo0.05 vs AMP-PE same genotype; ^Po0.05 vs WT
AMP-PE; yyPo0.001 vs vehicle same genotype and time bin. Drd1 / ,
D1-null mice.
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between time bin and treatment (F(5,110)¼ 7.46, Po0.001)
but not genotype.
Antipsychotic Drug Effects on LI Reduction by AMP in
D2 / Mice
AMP disruption of LI in Drd2 / mice was attenuated by
both drugs tested, haloperidol and clozapine (Figure 2b),
demonstrating that clozapine and haloperidol do not
require the presence of D2 to attenuate AMP disruption
of LI. There were significant effects of pre-exposure
(F(1, 223)¼ 38.10, Po0.001), treatment (F(4, 223)¼ 5.01,
Po0.001), and an exposure treatment interaction (F(4,
223)¼ 2.92, Po0.05). There was no significant effect of
genotype nor interaction between genotype and other
factors (F’s o1). In WT PE groups, there was a significant
difference between AMP vs AMPþ haloperidol
(T21¼  2.68, Po0.05) and AMP vs AMPþ clozapine
(T19¼  3.43, Po0.05), and these differences were also
seen in Drd2 / mice; AMP vs AMPþ haloperidol
(T21¼  2.60, P¼ 0.01) and AMP vs AMPþ clozapine
(T19¼  3.66, Po0.005) (Figure 2b). Vehicle vs haloperidol
in PE WT group (T19¼ 2.2) was not significant. NPE
was significantly different from PE group in vehicle-
(T83¼  3.67, Po0.005), haloperidol- (T18¼  2.86,
Po0.05), AMPþ haloperidol- (T42¼  2.79, Po0.05), and
AMPþ clozapine-treated groups (T49¼  3.46, Po0.005)
but not in AMP- (T41¼  0.5) treated groups.
AMP Reduction of LI in Drd1 / Mice
We found that AMP disruption of LI is reduced in
Drd1 / mice compared with WT (Figure 3a). There
was a significant effect of drug treatment (F(1,121)¼ 4.23,
Po0.05), exposure (F(1,121)¼ 21.00, Po0.001), and geno-
type (F(1,121)¼ 4.05, Po0.05); the interaction between drug
treatment, exposure, and genotype was not significant.
There was a significant difference between AMP-WT and
AMP-Drd1 / in PE groups (T35¼ 2.24, Po0.05), sug-
gesting that AMP effect is moderated in D1 / mice.
There was a significant difference between NPE and PE
groups in vehicle- (T31¼ 2.97, Po0.05) and AMP-treated
Drd1 / (T28¼  2.5, Po0.05), suggesting LI in these
groups but not in AMP-treated Drd1þ /þ or vehicle-
treated Drd1 / groups.
AMP Locomotor Hyperactivity in Drd1 / Mice
AMP locomotor hyperactivity was maintained in both WT
and Drd1 / mice (Figure 3b). There was a significant
effect of drug treatment (F(1, 76)¼ 55.50, Po0.001) but no
effect of genotype. There was also a significant effect of time
bin (F(5,380)¼ 13.4, Po0.001) and an interaction between
time bin and drug treatment (F(5,380)¼ 9.44, Po0.001.
D1 Antagonist SKF83566 Effect on AMP Reduction
of LI in C57/BL/6 Mice
Figure 4 shows that pretreatment with SKF83566 at
0.1mg/kg but not 0.01mg/kg prevented AMP disruption
of LI. These data suggest that D1 antagonism can be
sufficient to prevent AMP disruption of LI. There was a
significant effect of exposure (F(1, 116)¼ 21.38, Po0.001)
and drug treatment (F(5, 116)¼ 2.65, Po0.05) and a drug
treatment exposure interaction (F(5, 116)¼ 2.33, Po0.05).
There was a significant difference between PE groups
AMPþ SKF 0.1mg/kg and AMP (T21¼ 2.6, Po0.05). There
was a significant difference between NPE and PE conditions
in vehicle (T21¼  2.37, Po0.05), AMPþ SKF 0.1mg/kg
(T21¼  2.4, Po0.05), and SKF 0.01mg/kg (T22¼  2.7,
Po0.01) groups but not in SKF 0.1mg/kg (T21¼ 1.9) or
AMPH-treated group (T’s o0.5).
DISCUSSION
These data show first that AMP disrupts LI in mice lacking
D2 receptors, demonstrating that AMP can influence
behavior in the absence of D2. This effect of AMP may be
specific to processes involved in learning to ignore
irrelevant stimuli, as locomotor hyperactivity induced by
the same regimen of AMP was blunted in mice lacking D2
receptors. Second, it was found that the D2 receptor is not
essential for antipsychotic drugs haloperidol and clozapine
to attenuate LI disruption induced by AMP. This has
important therapeutic implications as it suggests that it is
possible to modulate impaired ability to ignore irrelevant
stimuli induced by a hyperdopaminergic state without
interaction with D2. Third, AMP disruption of LI was
blunted in the absence of D1, suggesting that its effects to
disrupt LI may require D1. Hyperactivity induced by AMP
at the same dose was not affected in the absence of D1,
suggesting dissociation between the effects of AMP on LI
and on locomotor activity. AMP disruption of LI was
attenuated by the D1 antagonist SKF83566, suggesting
further that D1 merits further investigation in the mediation
of AMP disruption of LI.
Understanding the biological basis of the cognitive effects
of AMP and how it affects the selection of information are
Figure 4 D-Amphetamine (AMP) reduction of latent inhibition (LI) in
wild-type (WT) mice is attenuated by pretreatment with SKF83566 at
0.1mg/kg but not 0.01mg/kg. *Po0.05 non-pre-exposed (NPE) vs pre-
exposed (PE) same drug; þPo0.05, þ þPo0.01 vs AMP-PE.
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important for the understanding of both its abuse potential
and psychotomimetic effects. AMP produces a wide variety
of behavioral effects, including psychosis, locomotor
hyperactivity, stereotypy, self-administration, and disrup-
tion of sensori motor gating in a variety of species (Angrist
et al, 1980; Cole, 1978; Hutchison and Swift, 1999; Mansbach
et al, 1988; Marriott, 1968; Ralph-Williams et al, 2002). A
consistent feature of these behavioral effects of AMP is that
they are prevented by antipsychotic drugs that block D2,
leading to their application as animal models relevant to
schizophrenia. Studies in null mice also suggest that D2
plays a crucial role in mediating AMP behavioral effects
(Kelly et al, 2008; Ralph et al, 1999). We show that D2 is not
essential for AMP to exert its disruptive effect on LI, yet
hyperactivity induced by the same dose and regimen of
AMP is reduced in the absence of D2. Reduced locomotor
activity in Drd2 / mice replicates previous findings
using mixed background strains (Kelly et al, 1998). Data
suggest that acute stimulatory effects of AMP using this
dose and treatment regimen may require D2. Statistical
interaction between genotype and treatment suggests that
this is distinguishable from baseline reduction in activity in
Drd2 / mice. This finding is consistent with evidence
showing reduced acute stimulatory effects of methamphe-
tamine in Drd2 / mice (Kelly et al, 2008).
Preserved AMP disruption of LI in Drd2 / is
consistent with pharmacological studies indicating no effect
of direct D2 agonist apomorphine on LI in rats (eg Broersen
et al, 1999, Lacroix et al, 2000). It is notable that in some
cases where LI has been disrupted by apomorphine, it is
NPE disruption that produced the loss of LI, making effects
on LI per se difficult to interpret (eg Melo et al, 2009, Shao
et al, 2010).
As AMP acts via presynaptic mechanisms to increase the
release of a number of neurotransmitters, including
noradrenaline and serotonin, as well as DA, it is possible
that its primary DAergic mechanism is devolved to a
different mechanism in compensation for developmental
absence of D2 in Drd2 / mice. There is electrophysio-
logical evidence that firing of DA neurons induced by AMP
in the ventral tegmental area switches to a noradrenergic
mechanism in the pharmacological absence of D2, that is, in
the presence of a D2 antagonist (Cohen and Lipinski, 1986;
Shi et al, 2000). Most antipsychotic drugs have affinity at
the noradrenaline a1 receptor (Cohen and Lipinski, 1986)
as well as D2 and other DA receptor subtypes, making
action through noradrenergic modulation one possible
mechanism.
Remarkably, we found that AMP disruption of LI is
attenuated by haloperidol and clozapine and does not
require the presence of D2. This surprising outcome
suggests that attenuation of AMP-induced abnormal
salience allocation by antipsychotic drugs can occur in the
absence of D2. There are a number of possible candidate
biological mechanisms. Drugs such as 5-HT2A receptor
antagonists have been shown to reverse AMP disruption of
LI in rats (Weiner and Arad, 2009); 5-HT2A antagonism is a
putative feature of ‘atypical’ antipsychotics and polymorph-
isms in 5-HT2A genes have been reported in schizophrenia
(Maier et al, 2008; Miyamoto et al, 2005). It is worth noting
that 5-HT2A receptors modulate activated but not basal
mesolimbic DA function (Schmidt and Fadayel, 1996;
Schmidt et al, 1995). However, while clozapine has
significant affinity for 5-HT2A receptors, haloperidol does
not, particularly at the dose used in this study. Interaction
with the cholinergic system is also a possible mechanism.
Muscarinic receptor M4 agonists have been suggested to
have antipsychotic potential (Shekhar et al, 2008; Dencker
et al, 2011) and have been shown to reverse AMP disruption
of LI (Barak and Weiner, 2011). Abnormal glutamatergic
neurotransmission, particularly at N-methyl-D-aspartate
(NMDA)-type glutamate receptors, has also been implicated
in schizophrenia (Olney et al, 1999). NMDA receptors are
regulated by the amino-acid glycine and drugs that interact
with transporters for glycine (GlyT1) may have antipsycho-
tic potential (Javitt, 2012). The GlyT1inhibitor SSR103800
has furthermore been shown to reduce AMP disruption
of LI (Black et al, 2009). The mechanism of the
D2-independent action of these drugs has yet to be
identified; however, AMP-disrupted LI in Drd2 / mice
may be of use as a novel model system to identify D2-
independent effects of these drugs. Their identification
could suggest neural strategies to remediate hyperdopami-
nergia-related disruption in a behaviorally specific manner
without interaction with D2.
One interpretation of these findings is that AMP effects in
Drd2 / mice differ from AMP effects in APD-treated
mice, broadly suggesting dissociation between pharmaco-
logical and genetic manipulations of D2 in the presence of
AMP. We have shown previously that in the absence of
AMP both potentiate low levels of LI and effects on
locomotor activity are consistent, indicating that this
dissociation is not a general phenomenon or even specific
for LI (Moser et al, 2000; Bay-Richter et al, 2009). One
possible explanation is that if AMP interacts with D1 to
disrupt LI as later experiments suggest, then the D1
antagonist action of APD would reverse AMP disruption
of LI by pharmacological antagonism. This would not be
seen in Drd2 / ; hence, a dissociation would be found.
It is also possible that Drd2 / mice differ in metabolism
or neural activity consequent to developmental absence of
Drd2 and this becomes unmasked in the presence of AMP.
We cannot determine from this study whether that is the
case or not, but this possibility does not alter the conclusion
from the study that D2 is not essential for AMP disruption
of LI.
Our findings indicate an attenuation of AMP disruption
of LI in female Drd1 / mice. This is consistent with the
observation that the diverse pharmacological actions of
psychotomimetic drugs, such as AMP, LSD, and PCP,
include effects on D1-mediated function (Watts et al, 1995).
Supporting a role for Drd1 / , we showed that SKF83566
attenuated the effects of AMP on LI. In contrast, we show
that AMP effects on locomotor activity are not reduced in
Drd1 / mice. AMP hyperlocomotor activity has pre-
viously been shown to be blunted in Drd1 / mice on
mixed background strains following acute and repeated
administration (Xu et al, 2000; Crawford et al, 1997).
We cannot determine whether this difference is due to
background strain difference, dose, or dosing regimen of
AMP. However, intact locomotor stimulation by AMP in
Drd1 / mice is clearly dissociable from both attenuated
locomotor stimulation seen in their Drd2 / counterparts
and attenuated disruption of LI in Drd1 / female mice
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using the same dose and regimen of AMP. There is a
possibility that this finding is sex-specific as male
Drd1 / could not be evaluated in these conditions, as
they do not show robust LI. Recently, it has been shown in
male rat studies that the D1 antagonist SCH23390 can
reverse AMP effects on LI (Nelson et al, 2012), suggesting
that these effects may not be specific to mice or females.
Previous rat studies have shown that LI disruption by
nicotine is also reversed by D1 antagonists. Nicotine (like
AMP) is thought to disrupt LI via mesolimbic DA release
and is reversed by antipsychotic drugs (Joseph et al, 1993;
Moran et al, 1996; Young et al, 2005). Taken together with
the present data, we suggest that the role of D1 in drug
effects to disrupt and potentially improve salience allocation
merits further investigation. It has been suggested that D1
antagonism may be important for the behavioral effects of
antipsychotics and may be secondary to D2 antagonism
(Josselyn et al, 1997; Miller, 1990, 2009). A potential role for
D1 in AMP disruption of LI is consistent with studies in rats
implicating D1 in overshadowing, a related measure of
salience allocation, other behavioral effects of AMP in other
species, as well as a more general role for midbrain D1 in
attentional accuracy (Liu et al, 2010, 2011; O’Tuathaigh and
Moran, 2002; Zelikowsky and Fanselow, 2010).
Translation of the outcome of experiments using animal
model systems to human psychosis and its treatment must
include the caveat of species and environmental differences
from the human condition. In these studies, mice were
water restricted; there is a possibility that this may be
important for demonstration of the effects we have shown.
In rats, it has been shown that drinking in water-restricted
rats can increase midbrain DA release (Young et al, 1992). It
is possible that cross-sensitization may have occurred
between effects of water restriction and AMP effects on
DA release in key brain regions such as the nucleus
accumbens. Sensitization of the locomotor response
induced by AMP has been shown specifically to involve
D1 (Vezina, 1996); further experiments would be required to
test this possibility.
CONCLUSION
We have demonstrated the principle that AMP, clozapine,
and haloperidol can exert behavioral effects in the absence
of D2 in mice. These D2-independent effects may be
behaviorally specific to the process of learning to ignore
irrelevant stimuli and allocating salience appropriately
as measured in LI. D1 merits further investigation in
the mediation of these effects. Identification of this
D2-independent mechanism may constitute a novel
behavior-driven approach to identify existing and candidate
antipsychotic drug actions that are behaviorally specific and
independent of D2.
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